Mylan Can't Decertify EpiPen Antitrust Action Ahead Of Trial

By Lauren Berg · December 15, 2021, 9:43 PM EST

A Kansas federal judge on Wednesday largely denied Mylan's bid ahead of trial next month to decertify antitrust class action claims accusing the pharmaceutical company of causing a delay in the...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Order

Case Information

Case Title

In Re: Epipen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation

Case Number

Court

Kansas

Nature of Suit

Personal Inj. Prod. Liability

Date Filed

August 04, 2017

Recent Articles By Lauren

August 09, 2024
Takeda Should Face Certified Antitrust Classes, Judge Says
August 06, 2024
Henrietta Lacks' Family Sues Novartis, Viatris Over HeLa Cells
August 02, 2024
5th Circ. Upholds Challenge To Surprise Medical Billing Rule
July 31, 2024
Wells Fargo Let Workers' Prescription Costs Soar, Suit Says
July 30, 2024
Cook Medical Vein Filter Claims Came Too Late, 7th Circ. Says
July 26, 2024
3rd Circ. Again Tosses J&J Talc Unit's 'Texas Two-Step' Ch. 11
July 19, 2024
House IP Committee Heads Unveil Drug Pricing Bill
May 21, 2024
Hawaii Wins $916M From Bristol-Myers, Sanofi Over Plavix
May 02, 2024
Walgreens Fights $1B Arb. Award Over COVID Test Contract
April 29, 2024
Pfizer Inks $25M Deal Ending Leftover Effexor Antitrust Claims